Pomerantz Law Firm Investigates Omeros Corporation for Potential Securities Fraud

The Pomerantz Law Firm is investigating potential securities fraud or unlawful business practices by Omeros Corporation and its officers following a negative regulatory opinion on narsoplimab. The stock price dropped significantly after the announcement.

By Pomerantz LLP · PR Newswire · July 9, 2026, 23:57 UTC

Tickers: $OMER

Topics: class action EMA rejection securities fraud

Read the full article at PR Newswire

More World news

CNBC Select Names Accredited Debt Relief Best for Debt Resources PR Newswire · November 12, 2026, 19:25 UTC
CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Tetra Tech Forecasts FY 2027 Revenue Between $4.425B and $4.625B Amid Backlog Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC